Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Liquidia Corporation is a U.S.-based biopharmaceutical company focused on the development and commercialization of inhaled therapies for patients with pulmonary hypertension and related cardiopulmonary diseases. The company operates within the biotechnology and specialty pharmaceuticals industries, with its primary value driver being proprietary drug–device combination products designed for pulmonary delivery. Liquidia’s lead commercial product is YUTREPIA, a dry-powder inhaled formulation of treprostinil approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company’s strategic differentiation is based on its proprietary PRINT (Particle Replication In Non-wetting Templates) technology, which enables precise control of particle size and shape to optimize lung delivery, dosing consistency, and patient convenience. Liquidia was founded in 2004 as a spinout from academic research at the University of North Carolina at Chapel Hill and initially operated as Liquidia Technologies before transitioning into a publicly traded biopharmaceutical company in 2018. Over time, the company shifted from a platform-technology licensing model to a product-focused commercial strategy centered on pulmonary hypertension.
Business Operations
Liquidia operates as a single-reportable-segment biopharmaceutical company focused on pulmonary hypertension therapeutics. Its core business activities include clinical development, regulatory approval, manufacturing, and commercialization of inhaled drug products using its PRINT technology. Revenue generation is expected to be driven primarily by sales of YUTREPIA following its U.S. Food and Drug Administration approval, with commercial infrastructure focused on specialty physician and hospital-based prescribing centers.
Operations are primarily domestic, with research, development, and manufacturing conducted in the United States. The company controls end-to-end manufacturing through its wholly owned subsidiary Liquidia Technologies, Inc., which operates a GMP-certified manufacturing facility. Liquidia does not rely on major joint ventures but maintains third-party relationships for certain clinical, regulatory, and commercial support functions.
Strategic Position & Investments
Liquidia’s strategic direction centers on establishing YUTREPIA as a differentiated inhaled treprostinil option in the pulmonary hypertension market, emphasizing patient convenience, dosing efficiency, and competitive positioning relative to existing nebulized therapies. Growth initiatives include expanding market penetration in PAH and PH-ILD and pursuing lifecycle management opportunities through additional indications and formulation enhancements.
The company has not pursued large-scale acquisitions but has made sustained internal investments in manufacturing scale-up, intellectual property defense, and commercial readiness. Its most significant strategic activity over recent years involved extensive patent litigation related to treprostinil formulations, which concluded with regulatory clarity enabling FDA approval. Liquidia continues to invest in emerging inhaled therapeutic applications leveraging its PRINT technology platform.
Geographic Footprint
Liquidia is headquartered in Morrisville, North Carolina, and its operations are primarily concentrated in North America. The company’s manufacturing, research, and corporate functions are U.S.-based, reflecting its current focus on the domestic pulmonary hypertension market. Commercial activities are directed toward specialized treatment centers across the United States.
While Liquidia does not yet have a broad international commercial presence, it maintains global intellectual property protections and has the capability to pursue regulatory approvals in Europe and other international markets over time. Its geographic influence is therefore primarily operationally domestic but strategically positioned for future international expansion.
Leadership & Governance
Liquidia is led by an executive team with experience in pulmonary medicine, drug development, and specialty pharmaceutical commercialization. The leadership team emphasizes disciplined execution, scientific rigor, and long-term value creation through differentiated technology and focused market strategy.
- Roger Jeffs – President and Chief Executive Officer
- Michael Kaseta – Chief Financial Officer
- Rajeev Saggar, MD – Chief Medical Officer
- Russell Ellison – Chief Legal Officer and Corporate Secretary
The company is governed by a board of directors with backgrounds in biotechnology, finance, and healthcare, providing oversight aligned with regulatory compliance and shareholder interests.